Bavarian Nordic to Present at the 14th Annual BIO CEO & Investor Conference in New York: The presentation will be held by Rolf Sass Sørensen, Vice President Investor Relations and Communications.
Vergrößern Bavarian Nordic to Present at the 14th Annual BIO CEO & Investor Conference in New York | Bild: © dpa

KVISTGAARD, Denmark, February 9, 2012 - Bavarian Nordic (NASDAQ OMX: BAVA) announced today that it will present at the 14th Annual BIO CEO & Investor Conference in New York on Tuesday, February 14, 2012 at 2:00 p.m. ET.

The presentation will be held by Rolf Sass Sørensen, Vice President Investor Relations and Communications.

About Bavarian Nordic

Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In infectious diseases, the company's lead program is IMVAMUNE®, a third-generation smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government.

For more information, visit www.bavarian-nordic.com.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via Thomson Reuters ONE

[HUG#1584214]